iwibacibem.wordpress.com
The funding came primarily from twonew investors, Proteo n said in a Thursday release: in Pa., and the Wellesley Hills, Mass., officer of . The additional funding brings the amountf of venture capital received by Proteonjto $84 million. Proteon Therapeutics, a privately held biopharmaceutical company, was founded in Kansas City and now is basesin Waltham, Mass., outside Boston. Its researcy facilities remain inKansas City. Proteon is developing a bloox vessel-dilating drug candidate. One of the main potential treatmentf benefitsof Proteon’s product is to help establish and maintaihn access points for dialysis patients.
Also Thursday, Proteon said the Food and Drug Administrationh hadgiven “orphan drug” designation to its drug candidatde for the treatment of two conditions in patientsw with end-state renal disease. Orphamn drug designation allows for certaihn tax credits and an extendedx period ofdata exclusivity, accordinyg to the release.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment